DTC ads made some cancer patients doubt their docs

Share this article:
A survey of patients at Harvard's Dana-Farber Cancer Institute found that 11% said ads for cancer-related drugs had made them less confident in their providers' judgment.

Of the 348 respondents to the survey, published in the Journal of Clinical Oncology, 86% were aware of DTC advertising, particularly television spots (77%), with little variation across clinical or sociodemographic factors except that patients were more likely to be aware of products specific to their cancer types.

Of those aware of ads, 17.3% said they'd talked to their healthcare provider about an advertised medication, though fewer than a fifth of those patients reported receiving a prescription for the drug in question. Patient perceptions of DTC ads were generally favorable, particularly among non-college graduates.

The researchers concluded that the respondents were highly aware of DTC for cancer-related treatments, that they found ads to be accessible and useful and that they prompted "a modest amount of patient-provider discussion but infrequent patient-reported changes in therapy."

Share this article:

Email Newsletters

More in News

Sales of Biogen MS pill pick up overseas

Sales of Biogen MS pill pick up overseas

Biogen Idec is seeing strong sales for blockbuster MS drug Tecfidera, especially overseas where it's beginning to catch fire this summer.

GSK second-quarter sales disappoint

GSK second-quarter sales disappoint

Executives urge analysts to focus on the company's long-term potential.

House bill would speed approval once EU OKs same product

House bill would speed approval once EU OKs ...

The Speeding Access to Already Approved Pharmaceuticals Act of 2014 would require FDA to expedite the review of pharmaceuticals that are already approved by the European Union